Skip to main content
ice cubes
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 
RT @Janetbirdope: #Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizu

Janet Pope Janetbirdope

1 month ago
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185
RT @Janetbirdope: #Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe

Janet Pope Janetbirdope

1 month ago
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022
RT @Janetbirdope: Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free

Janet Pope Janetbirdope

1 month ago
Positive study NUT when to use the Rx? PMR RCTof 1 g #rituximab once. Over 1 yr with more steroid free remission - curves separate by 21 weeks (steroids off) POS0269 @RheumNow @eular_org #EULAR2023 when to use it-COVID risk, ?prefer IL6i
gout.MTP1_.jpg
Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal. 
RT @drdavidliew: ARIAA: saw 18m results #EULAR2022
(alluded to at #ACR21)

High-risk ACPA+ clinically suspect arthralgia

David Liew drdavidliew

1 month ago
ARIAA: saw 18m results #EULAR2022 (alluded to at #ACR21) High-risk ACPA+ clinically suspect arthralgias Didn't progress to arthritis: after 6m abatacept: 92% vs 65% 12m after abatacept stopped: 65% vs 43% (tighter at points) How to pick those that benefit? POS0531 @RheumNow https://t.co/dkf1jU5gx7
RT @synovialjoints: As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here

Dr. Antoni Chan synovialjoints

1 month ago
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow
PSA2L.jpg
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  Here are my top picks from this year's meeting.
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap

Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights

Dr. John Cush RheumNow

1 month ago
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.https://t.co/ExCXY6Xbl4@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI
RT @doctorRBC: Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-control

Robert B Chao, MD doctorRBC

1 month ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
RT @doctorRBC: Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained R

Robert B Chao, MD doctorRBC

1 month ago
Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
×